Validation does not have to mean recreating every vendor test, rewriting every artifact, or burying teams under documentation nobody wants to read twice. The better path is knowing what the vendor can provide, what the regulated company still owns, and where risk-based evidence must close the gap.
This white paper helps life sciences teams clarify validation requirements and responsibilities for SaaS and cloud systems, including how to leverage vendor SDLC, testing, release management, documentation, and support while maintaining GxP accountability.
Use it to make validation more efficient, more defensible, and slightly less soul-taxing. We take our wins where we can.
What you will learn
- Clarify responsibility boundaries: understand what vendors typically provide and what the regulated company must still own.
- Leverage vendor evidence: use SDLC documentation, OQ testing, traceability, release notes, and support artifacts without duplicating low-value work.
- Apply CSA principles: focus validation effort on intended use, risk, critical thinking, automated testing, and patient/product-quality impact.
- Close validation gaps: identify where customer-specific configuration, PQ, data integrity, change control, and ongoing maintenance require additional evidence.
Why validation responsibility matters
As life sciences organizations rely more heavily on SaaS and cloud technology vendors, validation becomes a shared-evidence model. Vendors may provide development controls, testing, documentation, release management, and support. The regulated company remains accountable for intended use, configuration, risk assessment, data integrity, and operational control.
FDA’s Computer Software Assurance guidance supports leveraging vendor testing and release management where appropriate. The opportunity is to reduce redundant work while keeping the validation package clear enough to defend during audits and inspections—and to keep electronic records aligned with 21 CFR Part 11 expectations.
KPIs to measure validation efficiency and control
Track metrics that show whether validation work is risk-based, traceable, and sustainable across releases.
What the white paper covers
- What to expect from vendors: SDLC documentation, OQ evidence, traceability, quality/compliance support, and reference artifacts.
- Where regulated companies remain accountable: intended use, vendor qualification, configuration, PQ, risk assessment, data integrity, and change control.
- Advantages of outsourcing validation: domain expertise, reduced risk, cost savings, release management, automated testing, and continuous compliance maintenance.
- How CSA changes the approach: less low-value documentation, more critical thinking, and more targeted automated testing.
Leveraging vendor evidence also raises the question of how you qualify and monitor those vendors over time—a discipline covered in third-party risk management. For SaaS and cloud systems where releases never stop, sustaining the validated state between vendor updates is where USDM Cloud Assurance keeps systems audit-ready.
Who should download it
- Quality, Validation, and CSV/CSA leaders modernizing SaaS and cloud validation practices.
- IT application owners managing releases, configurations, integrations, and vendor documentation.
- Compliance and Data Integrity teams ensuring electronic records remain complete, attributable, legible, contemporaneous, original, and accurate.
- Business process owners trying to move faster without weakening inspection readiness.
FAQ: Validation requirements and responsibilities
Who is responsible for validating a SaaS or cloud GxP system?
Responsibility is shared. The vendor typically provides development controls, testing, documentation, release management, and support. The regulated company remains accountable for intended use, vendor qualification, configuration, performance qualification, risk assessment, data integrity, and change control. Validation becomes a shared-evidence model rather than a single owner.
Can I rely on vendor testing instead of repeating it myself?
Where appropriate, yes. FDA’s Computer Software Assurance guidance supports leveraging vendor SDLC documentation, OQ testing, traceability, and release management to reduce redundant work. The goal is to reuse approved vendor evidence while keeping the validation package clear enough to defend during audits and inspections.
What still needs additional evidence after I leverage vendor artifacts?
Gaps that are specific to your environment: customer-specific configuration, integrations, workflows, performance qualification, data integrity, change control, and ongoing maintenance. These are where risk-based, customer-owned evidence closes the gap that vendor documentation cannot cover.
How does Computer Software Assurance (CSA) change the validation approach?
CSA shifts effort away from low-value documentation toward critical thinking and targeted, often automated, testing focused on intended use, risk, and patient or product-quality impact. The result is validation that is more efficient and more defensible, not simply lighter.
What are the advantages of outsourcing validation?
The white paper outlines domain expertise, reduced risk, cost savings, release management support, automated testing, and continuous compliance maintenance as advantages of partnering on validation rather than carrying every artifact in-house.